Transgene Presents 2018 Half-Year Results and Business Update
 
 
 
 - Transgene obtains $48 million in Tasly Biopharmaceuticals shares with the sale of the Greater China rights of TG1050 and TG6002
 
 - Key trials of Transgene’s immunotherapeutics to deliver results before the end of 2018 and over the course of 2019
 
 - Strong research capabilities put Company at the forefront of innovation
 
 *Oncolytic virus Invir.IOTM platform progressing well
 
 *An ambitious personalized therapeutic vaccine platform to be presented in the coming weeks
 
 - €33.0 million in cash and cash equivalents providing financial visibility until the end of September 2019
 
 .../...
 
                                            
                                            
                                         
                                            
                                            
                                         
                                            
                                            
                                         
                                            
                                            
                                        
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer